Rapid Micro Biosystems to Announce Second Quarter 2024 Financial Results on August 2, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024.

In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 2, 2024. The live webcast will be accessible on the Company’s website here and will be available for replay for one year from the webcast date.

About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual MQC testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.

For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Staff

Recent Posts

Hexaware Accelerates Delivery Solutions with a New Office in Chicago

CHICAGO, May 22, 2025 /PRNewswire/ -- Hexaware Technologies (NSE: HEXT), a leading global IT services…

36 minutes ago

Bulletin from the Annual General Meeting 2025

The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025,…

36 minutes ago

Lofta and Bloom Mental Health Partner to Bridge the Gap Between Sleep Apnea and Mental Health

SAN DIEGO, May 22, 2025 /PRNewswire/ -- Lofta, a leader in at-home sleep apnea testing…

36 minutes ago

AMA Establishes CPT Codes for Minimally Invasive ESD Procedure

CENTER VALLEY, Pa., May 22, 2025 /PRNewswire/ -- Olympus Corporation, a global medical technology company…

36 minutes ago

Tap Native Launches Precision Bidding by NPI, Empowering Pharma Marketers to Reach HCPs at the Individual Level

RAMSEY, N.J., May 22, 2025 /PRNewswire/ -- Tap Native, a leading healthcare-focused digital advertising platform,…

36 minutes ago

Former Amazon Leaders Launch General Medicine: A Healthcare Store That Gives Everyone Access to the Best Care in the World

General Medicine aims to make healthcare as easy as shopping online, while making sure customers…

37 minutes ago